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7ABSTRACT
Background. Endogenous estrogens are considered protective against
atherosclerosis, but the exact mechanism remains unclear. Estrogens exert
favorable effects on some of the major risk factors of atherosclerosis, including
beneficial changes in levels of low density lipoprotein (LDL) and high density
lipoprotein (HDL) and improved endothelial function. A widely investigated
feature is their role as antioxidants in lipoproteins. Estrogen fatty acid esters, a
unique class of hormones, are water-insoluble and they are carried lipoprotein-
bound in  circulation. In contrast to unesterified estrogen, they have been shown
to inhibit lipoprotein oxidation at physiological concentrations in vitro. Indirect
evidence suggests that they are formed in HDL by lecithin:cholesterol
acyltransferase (LCAT), but they have also been shown to be present in LDL.
Aims of the study. The present thesis is focused on the mechanism of
estradiol fatty acid esterification and incorporation in lipoproteins. Experimental
methods were set up to investigate  the formation, incorporation and transport
of estradiol esters in different lipoprotein fractions, to provide direct evidence
that the estradiol esters are generated by the function of LCAT and to
demonstrate that, once incorporated in HDL, the antioxidant potential of this
lipoprotein is increased, and finally, to investigate the effect of increased
triglyceride content in HDL on estradiol esterification in this class of lipoproteins.
Methods. Incubations of labeled estradiol were carried out first with plasma and
with ovarian follicular fluid in the presence and absence of an LCAT inhibitor,
followed by ultracentrifugal isolation of lipoproteins and analysis of the
radioactive material  associated with lipoproteins by chromatographic methods.
Next, incubation experiments were made with  isolated LDL, HDL2 and HDL3
with labeled estradiol (E2) with and without purified, exogenous LCAT.  The
effect of the triglyceride content of HDL3 on the E2 esterification reaction was
investigated by comparing esterification of E2 in hypertriglyceridemic HDL3 with
that in normotriglyceridemic HDL3.
Coincubations with native LDL and labeled E2-ester –containing HDL in the
absence and presence of cholesterol ester transfer protein (CETP) were made
followed by separation of these lipoproteins and analysis of attached
radioactivity. To investigate whether the resistance of HDL to oxidation is
increased when it contains E2 esters, an in vitro model system was established
with supraphysiological concentrations of E2 and purified LCAT to produce E2
ester -containing HDL particles. Copper-induced oxidation of purified HDL was
measured after incubations of i)  HDL alone, ii) HDL in the presence of
8exogenous E2, iii) HDL in the presence of exogenous LCAT, iv) HDL in the
presence of both E2 and LCAT and v) HDL in the presence of E2, LCAT and the
LCAT inhibitor. 
Results. The results demonstrated that LCAT-mediated synthesis of esterified
17ß-estradiol occurred mainly in HDL3, whereas HDL2 and LDL contained only
trace amounts of estradiol ester. Chromatographic analysis confirmed that the
radioactivity migrated in a position corresponding to that of 17β-E2 17-
monoester standard. The amount of radioactivity associated with HDL3
representing esterified E2 was significantly increased by addition of purified
LCAT but only limited increases of radioactivity were observed in HDL2 and LDL
with purified LCAT. After coincubations with E2 ester containing HDL, also LDL
contained E2 esters and this LDL- associated radioactivity increased as a
function of time in the presence of CETP. Increased triglyceride content caused
an accelerated E2 esterification in HDL. The LCAT-facilitated esterification and
incorporation of E2 esters increased oxidation resistance of HDL and there was
a significant correlation between LCAT activity and oxidation resistance.
Conclusions. HDL subfractions differ in their potential to regulate estradiol
esterification by LCAT. E2 17-ester formation occurred  almost exclusively in the
HDL3 particles both in the presence of endogenous HDL-associated LCAT as
well as after addition of exogenous LCAT. The experiments provide direct
evidence that E2 is esterified by LCAT in a dose –dependent manner, but also
other factors such as HDL composition and particle size modify these effects.
E2 esters present in HDL can be transported in plasma to LDL particles in a
process facilitated by CETP. 
In summary, LCAT facilitates the formation of hydrophobic E2 fatty acid esters
that become incorporated in HDL particles where they protect the lipoprotein
from oxidation. Based on experiments in vitro, E2 esters formed in HDL could be
transported to LDL in plasma via a partly CETP-dependent mechanism. This
may result, in theory, in effective antioxidant protection of LDL even after the
particles have penetrated the vascular wall. This would ultimately increase the
subendothelial antioxidant potential and hinder the foam cell formation.
Elucidation of the possible in vivo role of HDL-associated estrogen esters
requires further critical studies including experiments with physiological
hormone concentrations.
91. INTRODUCTION 
Cardiovascular disease (CVD) is the most common cause of death in the
Western world, and although premenopausal women are at lower risk than men
of same age, the incidence of CVD in women rises markedly after natural or
surgical menopause (McGill et al. 1979; Wenger et al. 1993). The protective
role of hormone replacement therapy (HRT) against CVD is controversial as
many observational studies have shown beneficial effects (Grady et al. 1992;
Barrett-Connor et al. 1998), but clinical trials have failed to show any
cardiovascular risk reduction (Hulley et al. 1998; Herrington et al. 2000).
However, endogenous estrogens are considered cardioprotective but the
underlying mechanisms are still unclear. Cardiovascular disease is the clinical
manifestation of the complicated process of atherosclerosis, and estrogens
exert favorable effects on some of the major risk factors of atherosclerosis,
including beneficial changes in levels of LDL and HDL (Walsh et al. 1991) and
improved endothelial function (Mendelsohn 2002). 
In the present thesis we have focused i) on estradiol fatty acid esters which are
members of a unique steroid family transported in the circulation exclusively
associated with lipoprotein particles, and ii) on one of the possible
atheroprotective mechanisms of endogenous estrogens: protection of
lipoproteins from oxidation. We have investigated the formation and transfer of
estradiol esters between lipoproteins, a process which is considered even a
prerequisite for the antioxidant effect of estrogens (Shwaery et al. 1997).
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2. REVIEW OF THE LITERATURE
This thesis concentrates on lipoprotein-associated estradiol and on the
underlying mechanisms by which endogenous estrogens may be
atheroprotective. Accordingly, the vast literature concerning HRT is beyond the
scope of this review. In addition, since the investigations have demonstrated a
central role for HDL, the major emphasis is on this lipoprotein.
 2. 1.  Overview of lipoprotein metabolism in atherosclerosis 
Atherosclerosis is a complex, multifactorial process which takes decades to
develop. The process begins with vessel wall inflammation, and the earliest
signs are increased endothelial permeability, migration of circulating monocytes
into the arterial intima followed by accumulation of cholesterol in monocyte-
derived macrophages (Ross 1999). 
2. 1. 1.  Low density lipoprotein 
Cholesterol is transported in plasma lipoproteins, predominantly in low density
lipoprotein (LDL). LDL is thought to be formed in two-step process by lipoprotein
lipase -mediated lipolysis of liver-derived very low density lipoprotein (VLDL)
and subsequent lipolysis of intermediate density lipoprotein (IDL) via the action
of hepatic lipase (HL). The fatty acids released in this process are taken up by
the involved tissues and by nascent HDL. Part of triglycerides can also be
transported to high density lipoprotein (HDL) in exchange for cholesterol esters
by cholesterol ester transfer protein (CETP). LDL can be removed from the
circulation via receptor-mediated endocytosis into the liver by hepatic LDL
receptors (Brown et al. 1981) or by LDL-receptor-related protein (LRP) which
together explain 75% of LDL clearance (Herz et al. 1988) or taken up by
peripheral cells through LDL receptors located on cell surfaces (Brown et al.
1986). Oxidatively modified LDL can be taken up by macrophages via
scavenger receptors resulting in cholesterol accumulation in the vessel wall
(Steinberg et al. 1989). 
2. 1. 2.  High density lipoprotein
Nascent HDL particles originate from apolipoprotein A-I (apoAI) –containing
particles secreted by the liver and intestine or from excess surface components
produced during lipolysis of chylomicrons or VLDL (Eisenberg 1984). Lipid-poor,
nascent HDLs (also called preß1-HDL particles) acquire cholesterol from
peripheral cells via the function of ATP-binding cassette transporter A1
(ABCA1) (Lawn et al. 1999) with apoAI serving as a ligand in the binding to
ABCA1 on macrophages. Phospholipid transfer protein (PLTP) continues
phospholipidation of nascent HDL in the circulation (Huuskonen et al. 2001).
Free cholesterol of the discoidal HDL is esterified by lecithin:cholesterol
acyltransferase (LCAT) and the esters form a lipophilic core  changing the
particle shape to spherical high density lipoprotein subclass 3 (HDL3) particles
(Rye et al. 1999) and subsequently to larger, more mature high density
lipoprotein subclass 2 (HDL2) particles. The esterified cholesterol in HDL
particles may be transferred to LDL and VLDL by CETP (Tall 1993), or
alternatively selectively taken up by scavenger receptor B1 (SR-B1), a HDL
receptor located mainly in the liver. This cholesterol can be converted to bile
acids and eliminated via the bile (Barter et al. 1996). SR-B1 receptors have also
been found in adrenal gland, ovaries, testes (Krieger 1999) and the vessel 
wall (Yeh et al. 2002). 
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Figure 1.  A schematic overview of lipoprotein metabolism. 
ABCA1, ATP-binding cassette transporter;  apoB, apolipoprotein B; apoAI, apolipoprotein A-I;
apoAII, apolipoprotein A-II; chol, cholesterol; CE, cholesterol ester; CETP,  cholesterol ester
transfer protein; HDL2, high density lipoprotein subclass 2; HDL3, high density lipoprotein
subclass 3; HL, hepatic lipase LDL, low density lipoprotein; LCAT, lecithin:cholesterol
acyltransferase; LDL-R, LDL-receptor; LPL lipoprotein lipase; SR, scavenger receptor, SR-B1,
scavenger receptor B class 1;  TG triglyceride; VLDL, very low density lipoprotein
HDL metabolism in hypertriglyceridemia
Hypertriglyceridemia results in an increased mass transfer of triglyceride from
triglyceride (TG)-rich lipoproteins to HDL through the action of CETP leading to
TG enrichment of HDL and reduction of the cholesterol content of each HDL
particle (Lewis et al. 1996). TG enrichment of HDL may have a significant
impact on the metabolism of HDL particles. These particles are more prone to
lipolysis by HL, resulting in a formation of smaller particles (Lamarche et al.
1999). ApoAI is in a more dissociable form on TG-enriched HDL and may be
shed from the particle (Liang et al. 1994). These mechanisms may all contribute
to a significant extent for the increased fractional catabolic rate (FCR) of apoAI
observed  in hypertriglyceridemic states and provide an explanation for the
inverse relationship between plasma triglyceride and HDL levels (Lamarche et
al. 1999).
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by the lipolytic activities of HL and LPL (Skinner 1994). HDL particles can be
classified according to particle size, protein composition or density in
ultracentrifugation, where the two main fractions are HDL2 and HDL3. HDL2
particles are less dense and contain a relatively higher amount of cholesterol
and phospholipids than HDL3 (Gotto et al. 1986). Small, dense HDL3 displays a
higher capacity to accept cholesterol from peripheral tissues and they are better
substrates for LCAT. They have also been reported to be more effective in
protection of LDL from oxidative stress (Yoshikawa et al. 1997) as compared
with large, light, lipid-rich HDL2. 
HDL particles can be artificially reconstituted. Discoidal reconstituted HDL
(rHDL) contains defined numbers of apolipoprotein molecules (usually one or
two molecules of apoAI) and a high amount of phospholipid molecules (usually
phosphatidylcholine)(Jonas 1986). These discoidal particles –in addition to
reconstituted spherical particles- are frequently used in in vitro studies to
delineate the biological effects of distinct proteins and lipids which are present
in native HDL.
Lecithin:cholesterol acyltransferase (LCAT) 
Lecithin:cholesterol acyltransferase is a soluble plasma enzyme that converts
cholesterol and phosphatidylcholines (lecithins) to cholesteryl esters and lyso-
phosphatidylcholines on the surface of HDL (Glomset 1968) and participates in
cholesterol movement from tissues into HDL (Fielding et al. 1995). Most of this
glycoprotein is synthesized by the liver and circulates in blood reversibly bound
to lipoproteins. LCAT preferentially binds to HDL, where apoAI, the major
apolipoprotein component of HDL functions as the main activator of LCAT
(Yokoyama et al. 1980).
Antiatherogenic functions of HDL
The inverse correlation between HDL cholesterol concentration and
atherosclerosis is well established (Nikkilä 1953; Gordon et al. 1977; Watkins et
al. 1986) and the mechanisms are under intense investigation. Reverse
cholesterol transport –a process of excess cholesterol flux from peripheral cells
to the liver (Fielding et al. 2000)- is at present considered the most important
antiatherosclerotic action of HDL. Also other antiatherogenic mechanisms have
been postulated, like inhibition of endothelial cell adhesion molecule expression
and protection of LDL against oxidation (Nofer et al. 2002). 
2. 2. Lipoprotein oxidation
2. 2. 1. Measurement of lipoprotein oxidation 
Oxidation of lipoprotein lipids generates conjugated dienes (rearrangements of
double bonds in polyunsaturated acyl chains) that absorb light at 234 nm
(Esterbauer et al. 1989). The kinetics of lipoprotein oxidation can be monitored
by measuring the formation of conjugated dienes by spectrophotometry
according to the method of Esterbauer et al (1989). A number of other methods
to measure lipoprotein oxidation have been described including thiobarbituric
acid reactive substances (TBARS) assay, which detects aldehyde products of
lipid peroxidation, as well as number of other assays for phospholipid and
cholesterylester hydroperoxides and aldehydic lipid peroxidation products
(Esterbauer 1996). 
When oxidation of LDL in vitro has been initiated by copper and monitored by
measuring the formation of conjugated dienes, the oxidation resistance of LDL
can be expressed as the length of time during which no significant lipid
peroxidation occurs. This period of inhibited oxidation, termed the 'lag time', is
thought to be partially due to the radical scavenging reactions of the anti-
oxidants contained in the LDL particle (Gieseg et al. 1994). Increase in the
antioxidative capacity of LDL causes prolongation of lag time and a shift to the
right of the oxidation curves (Fig 3).15
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Figure 3. An example of lipoprotein oxidation measured by determination of conjugated
diene formation as a function of time. The oxidation resistance of the two samples A and B is
compared as a difference in lag times, the lag time of curve A being 29 min and the lag time of
curve B 53 min (prolongation indicating increased antioxidant capacity).
2. 2. 2. Metabolic aspects of lipoprotein oxidation
The fact that human plasma is endowed with a number of antioxidant defense
mechanisms involving many free radical scavengers, reducing agents and
antioxidant enzymes suggests that the oxidation of lipoproteins occurs
preferentially in subendothelial space rather than in plasma (Frei et al. 1988).
The term “oxidation” is used here to include the process of lipid peroxidation
and the protein modifications that accompany or result from lipid peroxidation.
Lipoproteins have been reported to be oxidized by various vascular cells
including macrophages (Parthasarathy et al. 1986), lymphocytes (Lamb et al.
1992)  endothelial cells (Steinbrecher et al. 1984) and smooth muscle cells
(Heinecke et al. 1987). In vitro, iron and copper are used to modify LDL and
copper oxidized LDL resembles to some extent endothelial cell –modified LDL
in its chemical and biological properties (Esterbauer et al. 1992).
Susceptibility of LDL to oxidation is among other factors increased by reduced
particle size and  high content of polyunsaturated fatty acid (Korpela et al.
1999), and decreased by high vitamin E content in the particle (Tsimikas et al.
1998). It is presumed that lipid peroxidation in LDL begins in the acyl chains of
the phospholipids and propagates to the neutral lipids in the core of the particle,
which is later accompanied by fragmentation of apolipoprotein B and antigenic
changes in the protein (Steinbrecher et al. 1987). 
Oxidation of LDL and its intimal accumulation are considered crucial steps in
the development and progression of atherosclerosis, i. e. LDL must be
oxidatively modified to trigger the pathological events of atherosclerosis
(Steinberg et al. 1989; Witztum et al. 1991; Ross 1993; Heinecke 1998; Ehara
et al. 2001). This hypothesis is supported by a number of in vitro and in vivo
studies demonstrating the proatherogenic properties of oxidized LDL and the
occurrence of oxidatively modified LDL in atherosclerotic (Klatt et al. 1996). The
uptake of normal, unoxidized LDL is regulated by LDL receptors as increased
intracellular cholesterol concentration downregulates the cholesterol synthesis
and LDL-receptor expression (Brown et al. 1986). Oxidized LDL (oxLDL) is
taken up by a different receptor, a scavenger receptor of macrophages in vessel
wall, which does not recognize normal LDL. The scavenger receptor is not
downregulated by the inflowing cholesterol, which leads to accumulation of
cholesterol in intimal macrophages and subsequent development to foam cells,
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and, finally to formation of fatty streaks, the first visible signs of an
atherosclerotic arterial wall (Goldstein et al. 1979). 
HDL inhibits LDL oxidation and reverses the stimulatory effect of oxidized LDL
on monocyte infiltration (Parthasarathy et al. 1990; Berliner et al. 1995;
Mackness et al. 1995; Banka 1996). The principal lipid and protein constituents
of HDL may have antioxidant potential, but minor components of HDL have also
been implicated, including transferrin which can associate with apoAI (Kunitake
et al. 1992), and enzymes such as paraoxonase (Mackness et al. 1993; Watson
et al. 1995), platelet activating factor (PAF)–acetylhydrolase (Watson et al.
1995) and LCAT (Vohl et al. 1999; Mackness et al. 2000). In particular,
paraoxonase can hydrolyze oxidized phospholipids in minimally modified LDL
(mmLDL) (Watson et al. 1995), and reduce the accumulation of lipid peroxides
in copper-oxidized LDL (Mackness et al. 1993). 
However, also HDL moieties may become oxidized and the degree of oxidation
depends in part on the type, concentration, and duration of oxidant exposure.
Tyrosyl radical and hypochlorite both preferentially attack apoproteins rather
than lipids of HDL, with tyrosyl radical generating low levels of lipid oxidation
products (Francis et al. 1996). In contrast, the initial site of attack by metal ions
(copper, iron, and manganese), hydroxyl radical, and lipoxygenase appears to
be HDL lipids, with modification of apoproteins occurring secondarily (Garner et
al. 1998). 
The oxidation of HDL leads to impairment of its antioxidative actions (Mertens et
al. 2003) and also to decline in other atheroprotective properties like reduced
reverse cholesterol transport  (Morel 1994; Francis 2000) and decreased LCAT
activity (Maziere et al. 1993)
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2. 3. 3.  Estradiol esterification and estradiol esters in lipoproteins
E2 fatty acid esters are formed by the esterification of the hydroxyl at position C-
17ß in the D-ring with a (predominantly) long chain fatty acid (Kanji et al. 1999)
(Figure 4). Estradiol esters are synthesized in vivo in various tissues including
spleen, lung, uterus, liver and adipose tissue (Schatz et al. 1981) by direct
esterification of E2 (Larner et al. 1992) in a reaction catalyzed by acyl coenzyme
A : cholesterol acyltransferase (ACAT) (Martyn et al. 1987), but these E2 esters
are not secreted from the tissues into the circulation (Schatz et al. 1981).
Previous studies have provided indirect evidence that the esterification reaction
in blood and ovarian follicular fluid occurs in HDL particles and that the reaction
is catalyzed by a different enzyme,  LCAT (Shwaery et al. 1997; Hochberg
1998; Kanji et al. 1999; Lamarche et al. 1999; Lewis et al. 2001; Tikkanen et al.
2002) Pahuja et al. 1995) (see figure 4), which mainly esterifies cholesterol
(Pahuja et al. 1995; Pahuja et al. 1995). 
Figure 4. Formation of estradiol fatty acyl 17 ß ester in plasma.  The 17ß-hydroxyl in the D
ring is esterified with a long chain fatty acid in a reaction that can be catalyzed by LCAT. The
aromatic A ring has an intact hydroxyl group at carbon 3.
OH
E2 - 17ß ester
HO
OH
E2
HO
LCAT
 - C -CH2- CH2 - CH2 ... CH3
--O--
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The estradiol esters formed are transported in blood where they are exclusively
bound to lipoproteins (Janocko et al. 1983; Larner et al. 1992).
Unesterified E2 displays only a weak association with HDL particle (Tang et al.
1997), but E2 fatty acid derivatives are able to incorporate into lipoprotein
particles. Thus, these fatty acid ester derivatives of E2 are preferential structural
forms that associate with HDL.
Studies in both rats and humans have indicated that the plasma half-life of E2
fatty acid esters is significantly longer compared with unesterified E2 (Larner et
al. 1985) and their effects in various tissues (uterus, liver, brain, pituitary gland)
has been found to be more prolonged than that of unesterified E2 (Larner et al.
1985; MacLusky et al. 1989). This suggests that estradiol fatty acid esters could
function as a storage form of estradiol and be hydrolyzed to free hormone when
needed (Hochberg et al. 1990). 
There is evidence that the esterification reaction is a prerequisite for estradiol to
function as an antioxidant in LDL particles at  physiological levels, a conclusion
based on in vitro experiments with plasma in which physiological E2
concentrations were used (Shwaery et al. 1997). However, the antioxidant effect
of E2 added directly to LDL, but not to HDL, has reportedly been lost after
dialysis. This suggests that the E2 esters are formed in HDL and subsequently
transported to LDL (Abplanalp et al. 2000). 
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3.  AIMS OF THE STUDY
Estrogen fatty acid esters, a unique class of hormone derivatives, are water-
insoluble and they are carried in the circulation in lipoprotein particles. In
contrast to unesterified estrogen, they have been shown to inhibit lipoprotein
oxidation at physiological concentrations in vitro. 
The aims of the present study were:
1. To study the formation, incorporation and transport of estradiol esters in
different lipoprotein fractions ( I and II)
2. To provide direct evidence that estradiol is esterified by the function of
LCAT and then incorporated into HDL in the form of estradiol esters,
which subsequently increases the antioxidant potential of HDL (III)
3. To investigate the effect of HDL composition, in particular of increased
triglyceride content, on estradiol esterification (IV)
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4.  SUBJECTS, MATERIALS AND METHODS
4. 1. Subjects 
4. 1. 1. Samples of normolipidemic plasma (Studies I-IV) 
Blood was drawn from healthy, normolipidemic volunteers (aged, 21–35) who
were taking no medication, into EDTA-containing tubes. Plasma was prepared
by immediate centrifugation at 2500 x g, 15 min, at +4oC or 2 300 x g for 10 min
at +10oC and was used for experiments during the same day.
4. 1. 2. Samples of follicular fluid (Study I)
Fresh follicular fluid was obtained from aspirates of women undergoing oocyte
retrieval for in vitro fertilization at the Helsinki University Central Hospital.
Ovarian stimulation was induced by combining gonadotrophin releasing
hormone (GnRH) analog with gonadotrophins. The only lipoprotein that follifular
fluid contains is  HDL. Follicular fluid was centrifuged twice (2300 x g, 15 min, at
+10oC) to remove blood cells and granulosa cells as well as nonspecific cell
debris. 
4. 1. 3. Samples of hypertriglyceridemic plasma (Study IV) 
Blood was collected from 8 hypertriglyceridemic men (plasma TG 2.6-11.2
mmol/l) after an overnight fast into EDTA-containing tubes and centrifuged at
2300 g for 10 min at +10oC to obtain plasma. 
The study protocols have been approved by the Ethics Committee of the
Department of Obstetrics and Gynecology and  by the Ethics committee of
Department of Medicine, Helsinki University Central Hospital.
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4. 2. Materials and Methods
4. 2. 1. Sequential ultracentrifugation and purification of serum
lipoproteins
The lipoproteins were isolated by sequential ultracentrifugation (Havel et al.
1955) at the following cut-off densities: VLDL (d<1.006 g/ml), LDL (1.006< d <
1.063 g/ml), total HDL (1.063< d < 1.21 g/ml) HDL2 (1.063< d < 1.125 g/ml) and
HDL3 (1.125< d < 1.21 g/ml) using a Beckman Optima LE-80K ultracentrifuge
and a Ti 50.4 rotor. Prior to the incubation with E2 (see incubation of estrogen
with lipoproteins), ultracentrifugally isolated lipoprotein fractions were gel
filtrated on Sephadex G-25 (column dimensions 1 x 20 cm, Pharmacia Biotech,
Uppsala, Sweden) to remove EDTA and other small molecules. Lipoproteins
were eluted with 2.5-3 ml of phosphate buffered saline (PBS) pH, 7.4. 
4. 2. 2. Separation of esterified estradiol from non-esterified estradiol  
The lipoprotein fractions obtained by gel filtration on Sephadex G25 were
pooled and extracted four times with 2.5 volumes of diethyl ether:ethyl acetate
(1:1, v/v) by mixing them vigorously for 3 min. The water phase was frozen in a
dry ice-ethanol mixture and the ether phase was decanted into a glass tube.
The extraction was repeated four times and the combined ether phases were
evaporated to dryness under nitrogen.
In order to separate esterified E2 from the free E2, samples were
chromatographed on a Sephadex LH-20 hydrophobic matrix (column
dimensions 0.5 x 5cm, Pharmacia Biotech, Uppsala, Sweden) using
hexane/chloroform, (1:1, v/v) as the eluting solvent at room temperature. In
short, disposable Pasteur pipettes (145 mm, Volac) plugged with cotton were
packed to a height of 5 cm with a suspension of Sephadex LH-20 in
hexane:chloroform (1:1, v/v). After washing the columns with fresh solvent, the
dry samples were dissolved in 0.3 ml of hexane:chloroform (1:1, v/v) and
applied to the columns twice in 0.3 ml of the same solvent. The estradiol ester
fraction was eluted with 6 ml of hexane:chloroform (1:1, v/v). The non-esterified
estradiol fraction was then eluted with 5 ml of methanol. Both fractions were
evaporated to dryness under nitrogen and stored in the appropriate solvent
(ester fraction in hexane:chloroform, free fraction in methanol).
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4. 2. 3. Analysis of 17β-estradiol derivatives by thin-layer chromatography
(TLC). 
Samples (approx. 4000 dpm or all radioactivity available) obtained from the
17β-estradiol ”ester” fractions after chromatography on Sephadex LH-20 were
applied to TLC plates (20 x 20 cm, Silica gel 60, Merck, Germany) and
developed in a hexane/ethyl ether (1:7, vol/vol) solvent system. The following
non-radioactive standards were used: 17β-E2 (Steraloids, Newport, USA), 17β-
E2 17-stearate (Steraloids, Newport, USA), 17β-E2 3-oleate and 17β-E2 3,17-
dioleate. The last two esters were prepared as described previously (Meng et
al. 1999). TLC plates were dried in air and the location of the standards was
determined by visualization under ultraviolet (UV) light after rhodamine staining.
All bands were scraped from the TLC plates and counted directly for [3H]
radioactivity in a liquid scintillation counter (Rack-beta, Wallac, Turku, Finland).
17β-estradiol and 17β-estradiol 17-ester fractions of the samples were identified
by comparing their Rf-values to those of the standards (Studies I, II and IV).
4. 2. 4.  Incubation experiments with estradiol
Plasma (Study I)
Labelled [2,4,6,7-3H(N)] 17β- E2 (specific activity of 72 Ci/mmol,  New England
Nuclear, Boston, USA) in 0.5 mol/l N-2-Hydroxyethylpiperazine-N´-2-
ethanesulphinic acid sodium salt (HEPES) was added to plasma to reach a final
concentration of 2 x 106 cpm/ml (corresponding to 52 nmol/l E2) in a total
volume of 4 ml. The mixture was incubated for 24 h at +37oC in the absence
and presence of 1.5 mmol/l dithionitrobenzoic acid (DTNB) (Sigma, St. Louis,
MO). 
Follicular fluid  (Study I)
Incubations with follicular fluid were performed identically to the plasma
incubations during the same experimental set.
Lipoproteins ( Studies I-IV)
Study I: Transfer of [3H] estradiol-17ß between lipoproteins 
Purified, non-radioactive LDL (described under isolation and purification of
lipoproteins) was incubated with HDL isolated from the same subject, which
contained [3H]-E2 esters (prepared by incubation with plasma as described
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above). Incubations were carried out in 3 ml PBS, each incubation contained
HDL corresponding to 12,500 cpm (HDL protein between 0.3 and 0.9 mg). The
amount of LDL (defined as LDL protein) used in each incubation was half of the
HDL protein used (i.e. 0.15–0.45 mg). The incubations were carried out in the
absence as well as in the presence of various amounts of CETP at +37oC for 3,
6, 12 and 24 h. After incubations, lipoproteins were reisolated by 24h
ultracentrifugation  as described under Isolation of lipoproteins. The transfer of
[3H]-E2-17ß esters from HDL to LDL was measured by determining the
radioactivity in both donor (HDL) and acceptor (LDL) lipoproteins (Study I)
Study II: Incubation of LDL, HDL2, HDL3 and rHDL with [3H]-E2 
[3H]-E2 in 0.5 mol/l HEPES buffer was added to ultracentrifugally isolated and
purified HDL as well as to the major HDL subfractions HDL2 and HDL3 (1 mg or
2 mg protein in 3 ml TBS (Tris-HCl buffer, pH 7.4) to give a total radioactivity of
200 000 dpm (corresponding to 1.3 nmoles of E2). For comparison, incubations
were carried out using LDL, and reconstituted discoidal HDL (rHDL,
apoAI/cholesterol/egg PC in a molar ratio of 1:8:140). The mixture was
incubated at +37oC for 24 h in the absence or presence of LCAT (activity 10-74
nmol/h/ml) as well as in the absence and presence of DTNB, final concentration
of 3 mmol/l. 
Study III: Incubation of HDL with non-radioactive and radioactive estradiol  
Estradiol-17ß (concentration of E2 prior to incubation step was 300 µmol/l in the
final experimental solution) was added to HDL (1 or 2 mg total protein) in total
sample volume of 1.5-3 ml and the mixture was incubated at +37°C for 24 h in
the absence or presence of exogenous purified LCAT (activity 16.9 nmol/h/ml  ±
1.0 (SEM), range 1.6 - 44.7 nmol/h/ml, n=10) as well as in the absence or
presence of the LCAT inhibitor, DTNB, final concentration 3 mmol/l.
Simultaneous experiments were made with labeled 17ß-estradiol in 0.5 mol/l
HEPES buffer, added to HDL to give a total radioactivity of 2x105-2x106 dpm. 
Study IV: Incubation of HDL2 and HDL3 isolated from normo- (NTG) and
hypertriglyceridemic (HTG) males with radioactive and non-radioactive
estradiol 
[3H]-E2 in 0.5 mol/l HEPES buffer  was added to the HDL2 (200 µg  protein in
2.5 ml) or HDL 3 (600 µg protein in 2 ml) solution to give a total radioactivity of
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2x106 dpm. The mixture was incubated at +37°C for 24 h in the absence or
presence of exogenous purified LCAT. The same amount of exogenous LCAT
was added to HTG and NTG samples in each experiment, taking in the
consideration that the activities of different LCAT preparations varied between
3.7 and 37.2 nmol/h/ml (median 15.6 nmol/h/ml) in the 7 different experiments.
Parallel incubation experiments with HDL subfractions were made with non-
radioactive estradiol-17ß in the presence and absence of exogenous LCAT, as
well as control incubations without addition of estradiol. Altogether 7 different
experiments were carried out using simultaneously  both HTG and NTG
samples with the exception of one incubation with two HTG samples. E2-ester
enriched HDL3 was used in oxidation experiments.
Following incubations in all experiments, the lipoproteins were purified by size-
exclusion chromatography on Sephadex G-25 to remove small molecular
weight substances not associated with HDL particles. Protein concentration was
determined by the method of Lowry et al (1951). Radioactivity in the eluted
fractions was determined by liquid scintillation counting (Rack-beta, Wallac,
Turku, Finland). The proportion of generated, lipoprotein-associated E2 esters
was measured by a recently developed quantitative method by Vihma et al
(Vihma et al. 2003). 
4. 2. 3.  Preparation of reconstituted discoidal HDL (rHDL)
The sodium cholate dialysis method was used essentially as described
(Jauhiainen et al. 1986) in the preparation of rHDL discs from human
apolipoprotein A-I, egg phosphatidyl choline (PC) and cholesterol. Purified
human plasma apoA-I was kindly provided by Dr Peter Lerch, Swiss Red Cross,
Bern, Switzerland. Briefly, reaction mixture contained apoAI/cholesterol/egg
PC/sodium cholate in a molar ratio of 1:8:140:140. 
ApoAI was added into detergent-containing lipid dispersion and all the
incubations were performed in 10 mmol/l TBS, pH 7.4 containing 1 mmol/l
EDTA. First the reaction mixture was incubated at +25oC for 20 min with slight
shaking. Exhaustive dialysis to remove sodium cholate was carried out at +4oC
against 5 l of 10 mmol/l TBS –1 mmol/l EDTA buffer, pH 7.4 (changing fresh
buffer 4 times during dialysis period). After dialysis the discoidal rHDL
preparation was analyzed for the composition, purged with nitrogen and stored
at +4oC for a maximum period of 4 weeks.
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4. 2. 4. Purification and assay of human plasma lecithin-cholesterol
acyltransferase (LCAT)
Human plasma LCAT was purified from fresh lipoprotein deficient plasma d
>1.21 g/ml  by combining Phenyl-Sepharose CL-4B, ion-exchange and
hydroxyl-apatite chromatographies essentially as described previously
(Jauhiainen et al. 1986; Zhou et al. 1991), and LCAT activity was analyzed by a
radiometric assay (Jauhiainen et al. 1986). Enzyme preparations did not
express any CETP, PLTP, LPL or HL activity. Endogenous LCAT activity in
isolated lipoprotein fractions was determined prior to adding exogenous LCAT
(studies II-IV).
4. 2. 5.  Purification and assay of cholesterol ester transfer protein (CETP) 
Purification of CETP from human plasma was performed essentially as
described (Ohnishi et al. 1990; Rye et al. 1998)  from the bottom fraction (d >
1.21 g/ml)  of  ultracentrifuged plasmapheresis plasma. CETP activity was
determined with a radiometric method in which CETP transfers radiolabeled
cholesteryl esters from LDL to HDL (Groener et al. 1986). The CETP-active
fractions were stored at –70oC until use. The activity of CETP in different
purified batches varied between 15 and 25 nmol /ml /h. Purified CETP did not
contain PLTP, LCAT, LPL, or HL activity (Study I). 
4. 2. 6.  Other analytical methods
HDL-associated estradiol and its fatty acyl derivatives in the samples were
measured in a single experiment (Study IV) by the recently published method
(Vihma et al. 2003). The concentrations of apoAI and apoB were measured with
commercial kits by an immunoturbidometric assay (Orion Diagnostica, Finland),
and concentrations of cholesterol (Boehringer Mannheim, Mannheim,
Germany), triglycerides (Roche, Switzerland), and phospholipids (Wako
Chemicals, Germany) by enzymatic tests. Concentration of unesterified E2 was
measured by RIA (Sorin Diagnostics, Italy). 
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4. 2. 9.  Statistical analyses
Statistical analyses were carried out with SPSS 9.0-program for Windows. Data
are expressed as the mean ± standard error of the mean (SEM) or when the
data were not normally distributed, as median and range. Between-group
differences were assessed by unpaired t-test, variables with skewed distribution
were log10 transformed before the analyses. Continuous variables were
compared between the groups by univariate analysis of variance (ANOVA).
Correlation coefficients (r) for the associations between characteristics were
examined either by Pearson’s correlation analysis or Spearman’s non-
parametric correlation analysis, when appropriate.  
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5. RESULTS
5. 1. Formation of 17ß-estradiol 17-monoesters in HDL 3 subclass by
LCAT (Study I and II) 
Incubation of [3H]E2-17ß with  follicular fluid and plasma
Following incubation of [3H]E2-17ß with follicular fluid as well as normolipidemic
male plasma with and without DTNB, LDL and HDL were isolated by a
combination of ultracentrifugation and gel filtration on Sephadex G25. Figure 4
shows that there was a significant amount of radioactivity associated with the
protein fractions (fractions 7-9) of HDL (Fig 4 A) and LDL (Fig 4 C) after plasma
incubations with radioactive E2. Results with HDL derived from follicular fluid
were identical. When  incubations were carried out in the presence of the LCAT
inhibitor DTNB, almost no radioactivity could be detected in the elution position
of lipoproteins (Fig 4 A-D) suggesting that esterification was a prerequisite for
incorporation of [3H]-E2-17ß into lipoproteins. 
Figure 4. The radioactivity elution patterns of plasma HDL after Sephadex G25 (A)
anSephadex LH-20 (B) columns and of plasma LDL after Sephadex G25 (C) and
Sephadex LH-20 (D) columns. 
Plasma was incubated with [3H]E2-17ß with and without DTNB for 24 h. After incubation, LDL
and HDL were isolated by sequential ultracentrifugation. HDL and LDL were purified by gel
filtration on Sephadex G25 (A, C) to remove unattached [3H]-E2 and protein and radioactivity
levels were analyzed. After extraction with ethylacetate/diethylether, samples were
chromatographed on Sephadex LH-20 (B, D) first in hexane-chloroform, to elute the [3H]-E2
esters (E) and the solvent was changed to methanol to elute free [3H]-E2 (F) (arrow indicates
start of methanol elution).
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Analysis of  radioactivity attached to lipoproteins
Following extraction of the lipoprotein-containing fractions with
hexane/chloroform and subsequent hydrophobic chromatography on Sephadex
LH-20, a major part of the radioactivity was eluted in the "ester fraction"
(indicated by “E”) and only a trace amount was detected in the "free fraction"
(indicated by “F”) in both HDL (Fig 4B) and LDL samples (Fig 4D). There was
no detectable radioactivity in the "ester" fraction of the sample that was
incubated in the presence of DTNB (Fig 4B, Fig 4D). The "ester fractions" were
further analyzed by TLC that offered further evidence that most of the
radioactivity migrated in the same position as the ester standard (E2-17ß-
stearate, Rf-value 0.27).
Some samples from the saponified ester fraction were chromatographed on
Sephadex LH-20 (9% toluene in methanol), which separates estrone, 17ß-E2,
and estriol from each other showing that estrone or estriol was not present (data
not shown). This excluded the possibility of esterification and incorporation into
HDL of estrone or estriol formed from 17ß-E2.
Effect of exogenous, purified LCAT on 17β-estradiol esterification in HDL.
To find direct evidence of the role of LCAT in the estradiol esterification, isolated
HDL was incubated with labeled E2 in the presence and absence of exogenous
LCAT. The radioactivity peaks coincided with the protein peak after gel filtration
on Sephadex G25. Also, addition of  exogenous LCAT significantly increased
the esterification and incorporation of [3H]-E2 into HDL (p<0.05) whereas
addition of DTNB significantly decreased this effect (p<0.005). When
theincubations of HDL with [3H]-E2 were carried out by adding increasing
amounts of exogenous LCAT (0, 36, 73 and 110 nmol/h/ml), a clear dose-
response in the esterification of 17β-estradiol (Fig. 5) was observed. The
esterification activity present in the absence of exogenous LCAT was probably
due to endogenous enzyme activity remaining in HDL after ultracentrifugation, a
finding observed also previously (Meng et al. 1999). Endogenous LCAT activity
ranged between 3-107 nmol/h/ml among the different HDL preparations used.
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ig 5  Effect of exogenous, purified LCAT on E2 esterification in HDL.
adioactivity associated with HDL after incubation of HDL, [3H]-E2 and increasing amounts of
CAT. Asterisks indicate significant differences vs. baseline (0 = no addition of exogenous
CAT; p<0.05), using ANOVA followed by pairwise comparison by t-test with Bonferroni
orrection. Vertical bars indicate mean ± SEM.
ffect of exogenous, purified LCAT on 17β-estradiol esterification in HDL
ubfractions and LDL
xperiments identical with those carried out with total HDL were performed
sing HDL subfractions, HDL2 and HDL3, as well as rHDL and LDL. A significant
eak of HDL3-associated radioactivity (Fig. 6C ) as well as rHDL-associated
adioactivity (data not shown) was recovered in the void volume after gel
iltration on Sephadex G25. Only a trace amount of radioactivity, however, was
ttached to HDL2 subfraction (Fig 6B) and LDL (Fig 6A).  
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Figure 6. Elution patterns of LDL, HDL2 and HDL3–associated radioactivity after gel
filtration on Sephadex G25.
 LDL, HDL2 and HDL3 were incubated with [3H]-E2 in the presence  (  ? )  or in the absence
(      ) of exogenous LCAT. Incubations with DTNB ( O ) are also shown. After incubation,
lipoproteins were purified by gel filtration on a Sephadex G25 column. Panel A: incubation with
LDL (p<0.0005, LDL vs. HDL3 in the absence of exogenous LCAT;  p<0.003, LDL vs. HDL3 in
the presence of exogenous LCAT); Panel B: incubation with HDL2  (p<0.00001, HDL2 vs. HDL3
in the absence of exogenous LCAT;  p<0.002, HDL2 vs. HDL3 in the presence of exogenous
LCAT); Panel C: incubation with  HDL3 (p=0.07, HDL3 + LCAT vs. HDL3 – LCAT). Wilcoxon
signed-rank test was used for statistical analysis. Arrows indicate the fractions containing
proteins.
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Presence of label in the HDL3-fraction without addition of exogenous LCAT  was
due to endogenous HDL3-associated LCAT-activity, which ranged between 22
and 50 nmol/h/ml. Endogenous LCAT activities in LDL and HDL2 were very low,
ranging between 0.1 and 1.2 nmol/h/ml for LDL and between 0 and 4.2
nmol/h/ml for HDL2. Addition of purified LCAT to the incubations enhanced the
formation and incorporation of 17β-E2 17-esters in the presence of  HDL3
(p=0.07) and rHDL (p<0.05). Addition of LCAT to HDL2 or LDL caused only a
small increase in the radioactivity associated with these lipoproteins
(p<0.00001, HDL2 vs. HDL3 in the absence of exogenous LCAT;  p<0.002;
HDL2 vs. HDL3 in the presence of exogenous LCAT; p<0.0005, LDL vs. HDL3 in
the absence of exogenous LCAT;  p<0.003, LDL vs. HDL3 in the presence of
exogenous LCAT).
 
Extraction with ethylacetate/diethylether (1:1) followed by Sephadex LH-20
chromatography indicated that the radioactivity attached to total HDL, HDL3 and
rHDL represented esterified [3H] 17β-E2 (data not shown). Again, further
analysis of the ester fraction by TLC confirmed that the radioactivity comigrated
with the 17-E2 17-stearate standard suggesting that they represent 17β-E2 fatty
acid 17-monoesters.
Thus, in line with previous results (Abplanalp et al. 2000), E2 esterification
occurred in HDL, and not in LDL (even in the presence of exogenous LCAT).
Separate incubations with HDL subfractions indicated that E2 17-ester formation
occurred  almost exclusively in the small HDL3 subfraction. In addition, these
experiments provide direct evidence that E2 is esterified by LCAT in a dose –
response manner. The esterification by both endogenous and exogenous LCAT
occurred mainly in HDL3 subfraction. 
5. 2. The role of cholesterol ester transfer protein (CETP)  in the transfer of
17 estradiol esters (Study I)
Since E2 esterification occurs only in HDL, not in LDL, but after plasma
incubations or co-incubations with HDL, E2 esters are also present in LDL
(Meng et al. 1999; Abplanalp et al. 2000), we explored the possibility that [3H]-
E2-17ß-esters formed in HDL could be transferred to LDL by means of a CETP-
facilitated  process. 
Non-radioactive (native) LDL was incubated with [3H]-E2 ester -containing HDL
(12,500 cpm, obtained from plasma incubations with [3H]E2-17ß)  in the absence
and presence of CETP. As shown in Figure 7, during incubation without adding
CETP, the radioactivity in LDL increased proportionally with time, while
34
subsequently the radioactivity in HDL decreased. In the presence of purified
CETP (exogenous cholesteryl ester transfer activity per incubation: 8 nmol
cholesteryl ester transferred/h) this shift in radioactivity from HDL to LDL was
significantly accelerated (Fig. 7 ) The transfer of label from HDL (donor) to LDL
(acceptor) in multiple incubations was quantitated by determining the LDL/HDL
(cpm/cpm) ratio at various time points. The significance of the difference
between the mean LDL/HDL count ratios at each time point was analyzed by
paired t test (mean and SD): 3 h (0.23 ± 0.05 vs. 0.34 ± 0.06, n = 4), P = 0.028
without and with CETP. The corresponding values for the other time points
were: 6 h (0.40 ± 0.17 vs. 0.55 ± 0.15, n = 5), P = 0.032; 12 h (0.46 ± 0.09 vs.
0.76 ± 0.19, n = 3), P = 0.035; 24 h (0.82 ± 0.21 vs. 0.90 ± 0.26, n = 5), P =
0.388. 
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Figure 7. Incubation of native LDL with [3H]-E2 labelled HDL. [3H]-E2 labelled HDL was
incubated with non-labelled LDL, the lipoproteins reisolated by ultracentrifugation after 3, 6, 12
and 24 hours, and their radioactivity determined. Incubations were carried out in the absence
(Panel A) and presence (Panel B) of added purified CETP.  The transfer of label from HDL
(donor) to LDL (acceptor) was assessed in multiple incubations by determining the LDL/HDL
(cpm/cpm) ratio at various time points. The significance of the difference between the mean
LDL/HDL count ratios at each time point was analyzed by paired t-test (mean and S.D.): 3h
p=0.028 without and with CETP. The corresponding values for the other time points were: 6h
p=0.032; 12h p=0,035;  24h p=0.388. In other incubations additional CETP (final cholesteryl
ester transfer activity / incubation 20 nmol /h) was used (Panel C) which indicated further
enhancement of transfer.
To further investigate the role of endogenous CETP present in HDL, the transfer
activities of HDL ultracentrifugated once or twice were compared, the second
spin being used to remove residual endogenous CETP. The results indicated
that the amount of spontaneously transferred radioactivity was significantly
diminished, but not totally eliminated by this "washing" procedure (data not
shown). Analysis of the twice ultracentrifuged HDL samples by Western blotting
demonstrated that there still remained immunodetectable CETP in HDL in the
washed HDL. Thus, [3H]-E2 esters present in HDL could be transported to LDL
particles in a process that is facilitated by CETP.
5. 3. The effect of elevated triglyceride content of HDL on E2 esterification
(Study IV)
Experiments were made with both HDL subclasses 2 and 3 isolated from HTG
and NTG subjects, but in line with our results (Study II) accumulation of label in
HDL2 subclass was minimal (median radioactivity associated with HDL2 was
only 7% compared with that detected in HDL3). Thus, only results concerning
HDL3 are reported. 
5. 3. 1. Characteristics of HDL3 isolated from HTG and NTG subjects
To explore the difference in the ability of HTG vs NTG HDL3 to function as a
substrate in LCAT-facilitated estradiol esterification, HDL3 fractions were
isolated from the normotriglyceridemic (NTG) and hypertriglyceridemic (HTG)
subjects and their mass composition was determined (Fig. 8). The amount of
triglycerides was significantly higher in HTG HDL3 than in NTG HDL3 (mean  ±
SEM,  7.9 ± 0.9 mass % in HTG  vs 1.7 ± 0.2 mass % in NTG; p<0.001). Other
lipid parameters as well as apolipoprotein levels did not differ between the HDL3
species (p>0.1 for all). 
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Figure 8. Composition of HDL3 isolated form HTG (panel A) and NTG  (panel B) plasma.
The data present mass % values of individual components of HDL3. 
5. 3. 2. Detection of endogenous LCAT-activity in HTG and NTG HDL3 
Since LCAT-free HDL is difficult to obtain with conventional ultracentrifugal
methods, endogenous LCAT activity was measured prior to E2 esterification
experiments. At baseline, endogenous LCAT activity ranged between 2.3 and
54 nmol/h/ml (median 11.4 nmol/h/ml, n=8) in hypertriglyceridemic HDL3 and
between 3.5 and 23 nmol/h/ml (median 6.7 nmol/h/ml, n=6) in
normotriglyceridemic HDL3 incubations (Table 1). These data indicate that the
HDL3 particles have their own endogenous potential to launch estradiol
esterification due to tightly-associated LCAT activity. 
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Table 1. Incubation of HDL3 obtained from HTG- and NTG- individuals with
radioactive estradiol in the absence and presence of purified LCAT.
HTG NTG
LCAT – LCAT + LCAT – LCAT +
N 8 8 6 6
Tg (mmol/l) 5.7 5.7 1.0 1.0
Tg range (mmol/l) 2.6-11.7 2.6-11.7 0.45-1.76 0.45-1.76
[3H]-E2 ester (dpm) 49 600 a) 76 300 b) 18 000 a) 39 600 b)
[3H]-E2 ester range (dpm)20 900 - 66300 56 000 - 105 000 13 700 - 26 200 27900-46 300
LCAT act (nmol/h/ml) 11.4 28.8 6.7 20.6
LCATact range (nmol/h/ml) 2.3 - 53.6 22.7 – 74.4 3.5 – 22.9 13.9 – 60.1
Data are expressed as median. Statistical calculations were made using log-transformed data. a)
P<0.001, b) P<0.00005
5. 3. 3. Comparison of the LCAT-mediated esterification of E2 between
hypertriglyceridemic (HTG) and normotriglyceridemic (NTG) HDL3 as substrates 
In order to compare the function of HTG- and NTG-HDL3 as substrates for
LCAT in E2 esterification, HDL3 was incubated with [3H]-E2 in the presence and
absence of added, exogenous LCAT. The same amount of exogenous LCAT
was added to HTG and NTG samples in each experiment. After incubation, the
radioactive compound(s) associated with HDL3 particles as well as the final
LCAT activity were analysed. In 7 separate HDL3 incubations, final median
LCAT activity was 28.8 nmol/h/ml (range 22.7 - 74.4 nmol/h/ml) in HTG samples
while the final median LCAT activity was 20.6 nmol/h/ml (range 13.9 - 60.1
nmol/h/ml) in NTG samples (Table1). The radioactivity associated with HDL3
following each incubation is demonstrated in Fig. 10. Significantly more
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radioactivity representing esterified E2 was associated with HTG HDL3
compared with NTG HDL3, both in the absence (p<0.001) and in the presence
(p<0.00005) of exogenous LCAT.  The addition of exogenous LCAT (mean
added activity 15.6 nmol/h/ml) to the incubation mixture caused a significant
increase in HDL3 -associated radioactivity in both HTG HDL3 (mean increase 29
000 dpm) and NTG HDL3 (mean increase 20 000 dpm) (p<0.005 and p<0.0005,
respectively).
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Figure 10. Radioactivity associated with HTG- and NTG- HDL3 representing esterified E2.
Labeled 17ß-estradiol was added to the HDL3 in the absence (    ) and presence  ( ■ ) of added,
exogenous LCAT. Following incubation, the lipoprotein was purified by Sephadex G-25 and
radioactivity in the eluted fractions was determined by liquid scintillation counting. Significantly
more E2 esters were formed in HTG HDL3 than NTG HDL3 without the addition of exogenous
LCAT (p<0.001), addition of exogenous LCAT to the incubation mixture resulted in significant
increased E2 esterification in both hyper- and normotriglyceridemic samples: median increase
was from 49 600 to 76 300 dpm in HTG HDL3  and from 18 000 to 39 600 dpm in NTG HDL3
(p<0.005 and p<0.0005, respectively). Each experiment represents HDL3 from different
individuals.
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The median endogenous LCAT-activity was non-significantly greater in the HTG
group than in the NTG group, and this activity did not correlate with the higher
amount of label in HDL3. There was a highly significant correlation between the
HDL3 triglyceride content and radioactivity associated with HDL3 both in the
absence (r=0.744; p=0.01) and in the presence (r=0.739; p=0.002) of
exogenous LCAT in the incubation mixture as demonstrated in Figure 11. The
triglyceride content (mass%) of HDL3 did not correlate with endogenous LCAT-
activity. These results strongly suggest that increase in HDL3 triglyceride
content improves its substrate properties in the LCAT reaction and leads to
increased esterification of E2. 
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Figure 11. Correlation between triglyceride mass% of HDL3 and radioactivity associated
in HDL3 after incubation with [3H]-E2 in the absence (panel A) and presence (panel B) of
exogenous LCAT. Labeled 17ß-estradiol was added to the HDL3 solution in the absence and
presence of added, exogenous LCAT. Following incubation, the lipoprotein was purified by
Sephadex G-25 and radioactivity in the eluted fractions was determined by liquid scintillation
counting. Spearman’s correlation analysis was used in statistical analysis
As demonstrated in  Study II, E2 was present in HDL3 mainly in fatty acid ester
form. Analysis of the radioactivity contained in HDL3 by a combination of
hydrophobic gel chromatography Sephadex LH-20 and TLC demonstrated that
it co-eluted and comigrated completely with the 17ß-E2 ester standard. This
data confirms that the estradiol derivative bound to HDL3 is a fatty acid ester
and not unesterified E2.40
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5. 4. The effect of estradiol ester formation and incorporation into
lipoproteins on the antioxidant potential of lipoproteins (Study III)
In order to investigate the antioxidative effects of fatty acyl derivatives of
estradiol incorporated in HDL, E2 was incubated with HDL in the presence or
absence of purified LCAT and the kinetics of copper-facilitated HDL oxidation
was monitored. 
Figure 12 represents the copper-induced oxidation of HDL as a function of time
measured by Esterbauer method (Esterbauer et al. 1989). Incubation of HDL in
the presence of both exogenous estradiol and LCAT caused a marked shift of
the oxidation curve to the right. However, when only E2 or only exogenous
LCAT had been incubated with HDL, the corresponding HDL oxidation curves
moved halfway to the right between the oxidation curves of native HDL and the
curve resulting from the incubation of HDL with both E2 and LCAT (Fig. 12). 
Figure 12.  Effects of  E2 and  LCAT-generated E2 fatty acyl esters on copper-mediated
HDL oxidation. 
HDL was incubated with E2  in the presence ( ▲ , n=9 ) or absence  (    , n=7 ) of exogenous
LCAT. Incubations were also carried out without addition of E2 in the presence  ( ∆ , n=9 ) and
absence of LCAT ( ─ n=10).  After incubation, HDL was isolated and purified and oxidation was
started with CuSO4 and diene formation was monitored.
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Table 2 shows the mean lag times after incubation of i) HDL alone, ii) HDL in
the presence of exogenous E2, iii) HDL in the presence of exogenous LCAT iv)
HDL in the presence of both exogenous E2 and LCAT and v) HDL in the
presence of exogenous E2, LCAT and the LCAT inhibitor DTNB. There was a
significant increase in the lag time of HDL when both E2 and LCAT were
present in the incubation (p<0.0001). In contrast, when the incubations were
made in the presence of DTNB, no prolongation of lag time was detected when
compared with incubations of native HDL. Also incubations in the presence of
either E2 alone (p=0.013) or LCAT alone (p=0.002) resulted in a prolongation of
lag time compared with native HDL. This data emphasize the antioxidant role of
esterified estradiol associated with HDL, but also demonstrates some
antioxidant activity for LCAT alone. 
Table 2. Lag times of HDL oxidation.
Sample                                     n         Lag time (min)    P
HDL (native) 10 27.8 ± 4.2
HDL + E2 7 55.2 ± 8.6           0.013
HDL + LCAT 9 59.7 ± 4.2           0.002
HDL + E2 + LCAT 9 105.6 ± 10.7     <0.00001
HDL + E2 + LCAT + DTNB 3 25.1  ±   2.8         ns
Data presented as mean ± SEM, comparisons calculated vs. native HDL. HDL oxidations were
induced by addition of Cu++ and measured by monitoring diene formation at A234.
Prior to addition of exogenous LCAT, endogenous LCAT activity in isolated HDL
ranged between 1.6 and 20.8 nmol/h/ml (mean ± SEM: 10.0 ± 1.2 nmol/h/ml).
The amount of added exogenous LCAT activity varied between 8.7 and 26.9
nmol/h/ml (mean ± SEM: 14 ± 3.0 nmol/h/ml) resulting in a final activity of 16.9 ±
2.3 nmol/h/ml (range 1.6 - 44.5 nmol/h/ml) during all incubations. There was a
significant correlation between LCAT activity in the incubation mixture and the
lag time of HDL oxidation (Fig. 13 ). These results provide further evidence that
HDL-associated catalytically active LCAT provides antioxidant protection in our
in vitro system, thus representing one of the mechanisms that catalyze E2
esterification.
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Figure 13. Correlation between LCAT activity and lag time in HDL oxidation 
HDL was incubated with LCAT in the absence ( O) and presence ( ● ) of exogenous E2. After
incubation, the oxidation of  purified HDL was started with CuSO4 and followed by monitoring
diene formation.
Free (nonesterified) E2 and esterified E2 were quantitated in the HDL fraction by
a recently developed method (Vihma et al. 2003) in one of our experiments. The
addition of E2 and exogenous LCAT (final activity 17 nmol/h/ml) into the HDL
incubation mixture induced the formation of 380 pmoles E2 esters per 1mg
HDL-protein. Addition of DTNB to this incubation mixture caused a significant
reduction in both LCAT activity by 80% and in the concentration of E2 esters by
99%. When no exogenous E2 was added to the HDL incubation mixture, the E2
ester concentrations were 0.33 pmoles per 1 mg HDL-protein with added LCAT
and 0.17 pmoles per 1 mg HDL-protein without LCAT. 
0
20
40
60
80
100
120
140
160
180
0 10 20 30 40 50
LCAT activity (nmo/h/ml)
la
g 
tim
e 
(m
in
)
44
6. DISCUSSION
6. 1. The role of LCAT in 17ß-E2 esterification
Incubation of [3H]-labeled 17ß-E2 with human plasma and follicular fluid
produced a lipoprotein-bound [3H]-labeled product, most of which coeluted with
17ß-E2 ester fatty acid standards on a hydrophobic chromatography as well as
comigrated with E2-17ß monoester during TLC analysis. The addition of the
LCAT inhibitor DTNB to the incubations almost completely abolished the
lipoprotein-bound radioactivity, suggesting indirectly that the reaction was
catalyzed by LCAT, which is in line with previous studies (Pahuja et al. 1995;
Kanji et al. 1999). It has been presumed a role for LCAT in E2 esterification
based on the following observations: i) E2 esterification did not occur in
incubations with isolated LDL but it occurred in incubations with plasma
(Shwaery et al. 1997; Shwaery et al. 1998) and during coincubation of LDL and
HDL (Abplanalp et al. 2000), ii) E2 esterification was inhibited by an enzyme–
inhibitor, a well-known sulfhydryl reagent DTNB (Shwaery et al. 1997; Shwaery
et al. 1998), indirectly suggesting a role for LCAT.
The experimental system was designed to provide direct evidence for the role of
LCAT and to clarify the specific roles of the HDL2 and HDL3 subfractions in the
formation of E2 17-fatty acid esters. Experiments using total HDL demonstrated
a clear-cut dose-response for LCAT in E2 esterification i.e. stepwise increases in
E2 17-fatty acid ester formations were observed when increasing amounts of
LCAT were added to the incubations. Separate incubations with HDL
subfractions indicated that 17β-E2 ester formation occurred  almost exclusively
in the small HDL3 subfraction. 
It can be concluded that LCAT facilitates the esterification of 17β-E2 and the
magnitude/rate of esterification is dependent on the LCAT substrate used. From
a mechanistic point of view it is interesting that LCAT, which normally esterifies
the 3β-OH group of  cholesterol and several hydroxysteroids is able to facilitate
the fatty acylation of the 17β-OH group of estradiol. The specificity of the LCAT
enzyme toward various acyl acceptors has not been intensively investigated,
but sterol molecules such as β-sitosterol, cholestanol and desmosterol have
been shown to be esterified in human plasma, indicating that sterol molecules
other than cholesterol can also function as the fatty acyl group acceptors
(Skrede et al. 1974). Several steroids that function as substrates for LCAT lack
the side chain (Piran et al. 1979; Leszczynski et al. 1989). Similarly, 17β-E2 also
lacks the carbon side chain which suggests that the hydrophobic side chain of
sterols at carbon-17 is not a prerequisite for the acylation of the 3β-hydroxyl
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group. In the case of  17β-estradiol the A-ring is aromatic, and the hydroxyl
group at position C-3 is phenolic. This group is not fatty acylated because LCAT
requires that the sterol acyl acceptor has a 3β-configuration for the hydroxyl
group (Jonas et al. 1984). TLC-analysis in the present study clearly
demonstrated that LCAT catalyzed acylation of the 17β-OH group. 
Szedlacsek and co-workers (Szedlacsek et al. 1995) have investigated the role
of LCAT in forming fatty acid esters of oxysterols in lipoprotein particles. They
discovered that following esterification of the preferred site (3ß-hydroxyl group),
the 27-hydroxyl group was esterified by LCAT in vitro, which suggested that the
esterification at this less common site was dependent on particle size, i.e., the
physical characteristics of the lipoprotein particle surface appeared to influence
the LCAT reaction. Our data using 17β-E2 suggests that although the 17β-OH
group of E2 is located at the other end of the molecule opposite to the 3-OH
group it is well oriented at the enzyme active site and the fatty acyl-group can
be transferred from the acyl-enzyme intermediate. This is in line with the
findings of Kanji et al (Kanji et al. 1999). 
Although the results provide evidence that E2 17-esters are preferably formed in
HDL3 subfraction, direct conclusions can not be made concerning the underlying
mechanism. However, substrate specificity for LCAT-facilitated cholesterol
esterification has been widely investigated, and analogies to estradiol
esterification can be presumed. Activation of LCAT by apoAI has been
demonstrated to depend directly upon the binding of apoAI to a lipid surface
(Chung et al. 1979) and the physicochemical characteristics of the particle
surface where the interaction of LCAT with substrate takes place appear to be
important (Jonas 1986). Small HDL particles (HDL3bc) as well as discoidal
apoAI-phospholipid-cholesterol particles provide the most active surface
configuration for the LCAT reaction (Barter et al. 1985; Dobiasova et al. 1994)
whereas large HDL (HDL2b) particles may inhibit the enzymatic reaction (Barter
et al. 1984; Karpe et al. 1990). It is possible that the rate of  estradiol
esterification by LCAT is influenced by HDL surface configuration in the same
way as cholesterol esterification. 
6. 2. The transfer of E2 esters from HDL to LDL
The fact that 17ß-E2 esters have been detected in LDL (Study I, (Shwaery et al.
1998; Kanji et al. 1999; Abplanalp et al. 2000)), but incubations of isolated LDL
with E2 did not result in E2 esterification and incorporation (Study II), raised the
question how these lipophilic estrogen esters produced in HDL were transported
to LDL particles. We hypothesized that CETP could be responsible for this
transport of 17ß-E2 esters between lipoproteins. This was considered possible
since cholesterol and 17ß-E2 share a somewhat similar ring structure. It was
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demonstrated that coincubation of native LDL with HDL containing 3H-labeled
17ß-E2 ester in a buffer solution resulted in transfer of the label to LDL and that
this transfer was significantly accelerated by addition of purified CETP to the
incubation mixture (Study I). Conversely, "washing" of the HDL fraction by a
second ultracentrifugation reduced the spontaneous transfer, presumably due to
reduction of the CETP adhered to HDL particles. The study provides for the first
time in vitro evidence that CETP participate in the transfer of E2 esters (Study I).
The current results are compatible with the concept that this transfer may in vivo
occur directly from HDL3 to LDL. Another possibility is that the 17β-E2 17-esters
are retained in vivo in the HDL particle  during the LCAT-facilitated maturation
of HDL3 to HDL2 particles, and are then transferred from HDL2 to LDL. Either
way, LDL would receive powerful lipophilic antioxidant molecules which could,
in theory, increase the oxidation resistance of LDL particles. This is supported
by the reports of Shwaery et al (Shwaery et al. 1997) indicating that incubation
of physiologically relevant  concentrations of 17β-E2 with male plasma caused a
significant prolongation of lag times in an in vitro LDL oxidation system.  
CETP has specificity for both neutral lipids (cholesterol esters and triglycerides)
and phospholipids (Tall 1993). Our observation of the CETP facilitated
acceleration of the transfer of 17ß-E2 esters from HDL to LDL is topical, since
recent data have proposed a new model of the transfer reaction mechanism of
CETP. The model suggested that i) a hydrophobic pocket in the amino-terminal
domain of CETP may have a role in neutral lipid binding and transfer (Tall 1993;
Beamer et al. 1997) and ii) the N-terminal active site may be involved in
determining the substrate species specificity for the transfer (Kotake et al.
1997). Accordingly, the transfer of E2 esters might be mediated via this site. The
role of CETP in the transfer of two other neutral steroids,
dehydroepiandrosterone (DHEA) and pregnenolone, has also been investigated
(Provost et al. 1997), and the results indicated that the fatty acid esters of these
compounds were transferred from HDL to VLDL and LDL by a mechanism not
dependent on CETP. However, this observation does not contradict the
possibility that CETP mediates estradiol ester transfer, but suggests that DHEA
and pregnenolone esters have very weak or null affinity to the lipid-binding
pocket of CETP.  Additional studies are needed to elucidate in detail the CETP-
mediated transfer of E2 esters. Nevertheless, our data show that CETP is able,
at least in vitro, to transfer esterified 17ß-E2 from HDL to LDL particles. 
6. 3. Effect of increased triglyceride content of HDL on E2 esterification
Our data indicated that fatty acid esterification rate of [3H]-E2 in the HDL3
subclass increased with increasing mass % of triglyceride in HDL3 i.e. as HTG-
HDL3 had a significantly higher triglyceride content than that in NTG-HDL3,
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these TG-enriched HDL3 species also exhibited a greater accumulation of [3H]-
E2 fatty acid ester (Study IV). Previous studies have shown that E2 is esterified
with fatty acids in a LCAT-mediated reaction at position C-17 (Kanji et al. 1999).
LCAT is tightly bound to HDL particles, mainly to those in the HDL3 subfraction
and nascent discoidal HDL, and is only incompletely removed by sequential
ultracentrifugation (Dolphin 1992). This finding was confirmed in our studies
which showed significant but greatly variable endogenous LCAT activities in all
isolated HDL samples. There was a highly significant correlation between  the
label associated with HDL3 and total LCAT activity in both HTG- and NTG-
HDL3 incubations following addition of exogenous LCAT in the presence of [3H]-
E2 (Study IV). One possible explanation is that since the triglyceride-rich HDL3
particles become more susceptible to lipolysis by HL resulting in smaller particle
size (Lamarche et al. 1999), the high degree of curvature at the lipid/water
interface is a better setting for LCAT to function (Fielding et al. 1971; Pinon et
al. 1980). This results in enhanced rate of E2 fatty acid esterification, which is in
line with the central role of LCAT in E2 esterification. 
The underlying mechanisms explaining increased substrate properties of TG-
enriched HDL particles have been explored previously in functional PLTP
studies (Rye et al. 1998; Settasatian et al. 2001) and are applicable here. It was
demonstrated that the apoAI in TG-enriched reconstituted HDL can unfold more
readily in comparison to apoAI on the surface of TG-poor HDL. This may
prevent some α-helices of apoAI to interact with surface phospholipid fatty acyl
chains (Frank et al. 1997) and may enable it to interact in a more effective way
with LCAT and therefore function as a better substrate. Recently it was reported
that three arginine residues of apoAI located at the hydrophobic/hydrophilic
boundary of the amphipathic helix are critical for activation of LCAT (Roosbeek
et al. 2001). This region could be more available for LCAT in TG-enriched HDL
and interact better with LCAT, which could explain the strong correlation
between LCAT and accumulation of [3H]-E2 esters in HDL3. 
6. 4. Antioxidative effect of lipoprotein-bound E2 fatty acid esters
Estrogens have been suggested to possess strong antioxidant effects in vitro
(Maziere et al. 1991; Rifici et al. 1992; Sack et al. 1994; Ayres et al. 1996; Ayres
et al. 1998; Wakatsuki et al. 1998; Meng et al. 1999), but very little is known
about the factors that influence the expression of the antioxidant effects of
estrogens in vivo. However, studies by Shwaery et al (Shwaery et al. 1997;
Shwaery et al. 1998) have suggested an important role for conversion of
estrogens to lipophilic derivatives, which occur in plasma. Fatty acyl
esterification of estrogens is considered a prerequisite for their incorporation
into lipoproteins (Hochberg 1998; Abplanalp et al. 2000) and even a key event
for their antioxidant actions(Shwaery et al. 1997).  However, previous studies on
the antioxidant efficacy of E2 esters have provided only indirect evidence for the
following chain of events:  LCAT mediates esterification of estradiol, which
incorporates into lipoproteins, which in turn increases the oxidation resistance of
the lipoprotein particles. (Shwaery et al. 1997; Shwaery et al. 1998). Although
these studies have provided valuable information, they have not documented
direct proof that E2 esters are formed in HDL in a reaction catalyzed by LCAT
and that these E2 esters provide protection of HDL particles against oxidation.
We used an in vitro model system with supraphysiological concentrations of E2
and purified LCAT to produce E2 ester -containing HDL particles for studies of
oxidation resistance. The lag time of HDL oxidation significantly increased with
increasing contents of HDL- associated E2 esters (Study III). We estimated that
the amount of HDL-associated E2 esters observed in our experiments were
approximately 760 pmol/ml in plasma. Thus, the E2-ester concentrations
presented here are more than a 1000-fold excess of the E2-ester levels in
plasma in vivo, which have been measured recently in pregnant women 200-
750 pmol/l (Vihma et al. 2003). To our knowledge, the highest concentrations of
E2 esters in vivo have been determined in human ovarian follicular fluid (mean
106 nmol/l, range 60-260 nmol/l) (Vihma et al. 2001). However, in our study
(Study III) we used supraphysiological levels of E2 to study the basic
mechanism underlying the formation and function of HDL-associated E2 fatty
acid esters. Esterbauer’s method (Esterbauer et al. 1989) used in our
exp riments is very applicable for this kind of first step analysis, but it is
rela ively insensitive and requires sufficient amounts of antioxidants present
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essitating the use of high concentrations of E2. However, E2, although the
cipal human estrogen, is only one among many estrogens like estrone and
riol, which may contribute to the antioxidant protection of HDL, and to
sible differences between female and male HDL.
nctional endogenous LCAT provided antioxidant efficacy by enhancing
genous E2 esterification to some extent in the absence of added LCAT
udy III). Incorporation of estradiol fatty acyl esters in HDL was confirmed by
ntitating the free and esterified estradiol in HDL with a recently developed
sitive method (Vihma et al. 2003). In some experiments in which
rmacological E2 amounts were incubated with HDL under conditions of low
AT activity, also free E2 adhered to some extent to the HDL particles. On the
er hand, it has been previously demonstrated that under physiological
ditions nonesterified estradiol has low binding affinity to serum lipoproteins
hma et al. 2003). In Study III, greater estradiol ester contents in HDL were
ociated with prolonged oxidation lag times. The fact that also addition of
AT alone gave rise to increased antioxidant capacity is in line with results of
hl et al (Vohl et al. 1999)  who proposed that  scavenging free radicals was
 underlying mechanism for LCAT –induced antioxidation. 
us, two different mechanisms are suggested to explain the increased
istance to oxidation of HDL, one being the incorporation of E2 esters and the
er the inherent antioxidant activity of LCAT . We hypothesize that E2
erification and LCAT activity could have physiological roles together with the
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antioxidative enzymes carried by HDL, the platelet-activating factor
acetylhydrolase and paraoxonase (Tselepis et al. 1995; Watson et al. 1995).
These mechanisms may contribute to blocking the build-up of oxidized lipids in
HDL thus preserving its ability to inhibit LDL oxidation (Bowry et al. 1992; Hahn
et al. 1994). Appropriate in this context is also the observation demonstrating
that E2 esters formed in HDL are transported to LDL by a mechanism that is at
least partly dependent on CETP (Study I). Thus, E2 esters formed in HDL might
be important in protection of both HDL and LDL against oxidation and the
activity of both LCAT and CETP might have an important role in the build-up of
antioxidative capacity of LDL. 
There is currently methodologically no easy way to clarify in what position the
17ß-E2 esters are located in the lipoprotein structure, but for instance modern
NMR-technology might be a promising novel way to track the E2 ester location
in lipoproteins. One possibility is that they are aligned on the lipoprotein surface
in the same way as phospholipids, the fatty acid chains directed toward the core
and the ring nucleus with the hydrophilic A-ring hydroxyl group on the surface of
the lipoprotein, thus providing functionally essential conformation in the
antioxidant process, see Figure 14.
Figure 14. hypothetized location of E2 esters in lipoproteins.
chol, cholesterol; CE, cholesterol ester; PL, phospholipid; TG, triglyceride
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6. 5. Other possible antiatherogenic actions of lipoprotein-bound E2 fatty
acid esters
A recent study has proposed that HDL binds to the scavenger receptor B class I
(SR-BI) which is also expressed in vascular endothelial cells and delivers
estrogen to endothelial nitric oxide synthase (eNOS), thereby stimulating the
enzyme (Gong et al. 2003). The authors, however, did not measure esterified
estradiol and it is not clear how the estradiol activated eNOS. Recent
observations by Nofer et al. (Nofer et al. 2004) have presented critical aspects
stating that native estradiol concentrations in HDL are by far too low to explain
eNOS activation via SR-BI route. On the other hand, it is quite possible that
certain membrane domains of the endothelium may cluster molecules like
estradiol esters from native HDL and form high local concentrations thus being
able to facilitate/initiate relevant physiological responses. Interestingly, earlier
data on lipoprotein-bound non-estrogenic steroid esters have suggested that
they can be taken up into cells via lipoprotein receptors and further hydrolyzed
into free steroid forms (Provencher et al. 1992; Roy et al. 1992; Roy et al.
1993). In any case, it is quite evident that the possible physiological role of
HDL-receptor facilitated endothelial entry of HDL associated estrogen esters
must be assessed critically in future studies.
The experiments in this thesis were designed using supraphysiological
concentrations of E2 and were aimed at providing basic information concerning
the role of HDL composition changes in determining the esterification rate of
estrogens via the function of LCAT.  Our results indicate that LCAT facilitates
the formation of hydrophobic estradiol fatty acid esters that become
incorporated in HDL particles where they significantly increase its antioxidant
potential. These E2 esters can be transported to LDL via a mechanism which is
at least partly CETP-dependent. In physiological terms, estrogen esters
contained in HDL could enter the arterial subendothelial compartment.
Alternatively, E2 esters formed in HDL could be transported to LDL in plasma
resulting, in theory, in effective antioxidant protection of LDL even after the
particles have penetrated the vascular endothelium and become sequestered
from the water-soluble antioxidants in plasma. This would ultimately increase
the subendothelial antioxidant potential and decrease the foam cell formation.
Figure 15 summarises the hypothesized mechanism.
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Figure 15.  Suggested mechanisms of formation and transport of E2 esters as well as
possible atheroprotective mechanisms
E2 esters formed in HDL by LCAT could be transported to LDL in plasma partly via a CETP-
dependent mechanism resulting, in theory, in effective antioxidant protection of LDL even after
the particles have penetrated the vascular endothelium.
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7.  SUMMARY AND CONCLUSIONS
The present series of studies aimed at elucidating the mechanism and role of
estrogen fatty acid esterification in high density lipoprotein  in vitro and can be
summarized as follows:
I   HDL subfractions differ in their potential to regulate estradiol esterification by
LCAT. E2 17-ester formation occurred  almost exclusively in the small less
mature HDL3 particles both in the presence of endogenous HDL-associated
LCAT as well as after addition of exogenous LCAT.
II  The data demonstrate that E2 is esterified by LCAT in a dose –dependent
manner, but also other factors such as HDL composition and particle size have
an effect in the process.
III The results provide in vitro evidence that E2 esters present in HDL can be
transported in plasma to LDL particles in a process that is facilitated by CETP. 
IV The results prove directly that HDL-associated catalytically active LCAT
provide antioxidant protection by E2 esterification.
Elucidation of the possible in vivo role of HDL-associated estrogen esters
requires further critical studies including experiments with physiological
hormone concentrations.
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